Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 105

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 105
---
 of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The Series B Warrants will be issued separately from the common stock and/or pre-funded warrants and may be transferred separately immediately thereafter.

Exercisability

The Series B Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Series B Preferred Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).

Cashless Exercise & and Alternative Cashless Exercise

If, at the time a holder exercises its Series B Warrants, a registration statement registering the issuance of the shares of Series B Preferred Stock underlying the Series B Warrants under the Securities Act is not then effective or the prospectus contained therein is not available for the issuance of such shares, then the Series B Warrant may be exercised, in whole or in part, at such time by means of a “cashless

<div align='center'>59</div>

exercise” in which the holder shall be entitled to receive a number of shares equal of Series B Preferred Stock in accordance with the formula set forth in the Series B Warrant.

Following the receipt of Stockholder Approval, holders the Series B Warrants may effect an “alternative cashless exercise” at any time while the Series B Warrants are outstanding without making any cash payments. Under the alternative cashless exercise option, a holder of a Series B Warrant has the right to receive an aggregate number of shares of Series B Preferred Stock equal to the product of (i) the aggregate number of shares of Series B Preferred Stock that would be issuable upon a cash rather than a cashless exercise of the Series B Warrant and (ii) 3.0. Accordingly, it is highly unlikely that a holder of the Series B Warrants would wish to pay an exercise price in cash to receive .001 share of Series B Preferred Stock when they could instead choose the alternative cashless exercise option and pay no cash to receive .003 shares of Series B Preferred Stock. As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the Series B Warrants.

Fundamental Transactions

In the event we consummate a merger or consolidation with or into another person or other reorganization event in which our common stock is converted or exchanged for securities, cash or other property, or we sell, lease